[Medicamentous bezoar following pancreaticoduodenectomy: the combined use of cholestyramine and antisecretory medications as a risk factor in pancreatic surgery].
The authors describe a case of pharmaco-bezoar consisting of ingested cholestyramine which occurred post pancreaticoduodenectomy. Intestinal obstruction by a cholestyramine bezoar is a rare occurrence but is worthy of note in the post-pancreatectomy setting where there is often concomitant use of cholestyramine, proton pump inhibitors, and octreotide.
Gillion
J-F
JF
Unité de chirurgie viscérale et digestive, Hôpital privé d'Antony, Antony. jfgillion@wanadoo.fr
Jullès
M-C
MC
Deyme
J-P
JP
Chollet
J-M
JM
Lagneau
M
M
Sirieix
D
D
D000230:Adenocarcinoma / Q000601:surgery; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects; D000924:Anticholesteremic Agents / Q000009:adverse effects; D001630:Bezoars / Q000139:chemically induced* / Q000601:surgery; D002779:Cholestasis / Q000188:drug therapy / Q000209:etiology; D002792:Cholestyramine Resin / Q000008:administration & dosage / Q000009:adverse effects*; D003082:Colectomy; D044684:Colon, Transverse / Q000601:surgery; D003108:Colonic Diseases / Q000209:etiology* / Q000601:surgery; D004359:Drug Therapy, Combination; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology* / Q000601:surgery; D015282:Octreotide / Q000009:adverse effects; D009853:Omeprazole / Q000009:adverse effects; D010185:Pancreatic Fistula / Q000517:prevention & control; D010190:Pancreatic Neoplasms / Q000601:surgery; D016577:Pancreaticoduodenectomy / Q000009:adverse effects*; D054328:Proton Pump Inhibitors / Q000009:adverse effects; D012307:Risk Factors; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D000924:Anticholesteremic Agents; D005765:Gastrointestinal Agents; D054328:Proton Pump Inhibitors; D002792:Cholestyramine Resin; D009853:Omeprazole; D015282:Octreotide